MRPL46

Across TCGA pan-cancer cohorts, MRPL46 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MRPL46 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher MRPL46 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MRPL46 expression acts as an unfavorable survival marker, although some lineages such as GBM and UCEC show a favorable association.

GBM, UCEC, and HNSC are the cancer types where MRPL46 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.666	0.457	.008	12	view →
UCEC	OS	Tertile	All	1.000	0.910	.048	10	view →
HNSC	OS	Median	All	0.449	1.000	.023	8	view →
PDAC	DFS	Tertile	All	0.601	0.345	.005	8	view →
CCRCC	DFS	Tertile	II,III,IV	0.439	0.851	.021	7	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.784	.007	5	view →
LUAD	DFS	Quartile	III,IV	0.768	0.328	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MRPL46–GBM (OS)

Open the GBM breakdown →